ACTRN12622001024730尚未招募未知
The ALLIANCE Trial: testing the effect of expanding pharmacists’ current scope of practice on uptake of effective contraception among women seeking an emergency contraception pill or early medical abortion medicines using a stepped-wedge pragmatic cluster randomised controlled trial in community pharmacy
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 1,554
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- o limit 至 o limit（—）
- 性别
- All
入选标准
- •PHARMACISTS
- •Those working in community pharmacies, located in either metropolitan, regional or rural areas of NSW, VIC and the NT, that have: A) Quality Care Pharmacy Program (QCPP) accreditation; B) A private consultation room; C) At least one pharmacist who works at least 30 hours per week (0.8 FTE) willing to commit to participation, D) participating pharmacist is accredited to dispense MS 2-Step (medical abortion medicines) and; E) consent from the pharmacy owner for the pharmacy to participate.
- •Any woman** attending the pharmacy for the purpose of purchasing the ECP or to fill a prescription for MS-2 Step, who: 1) Gives informed consent to participate in and adhere to trial requirements, and; 2) Is willing to give contact details and be contacted by phone/SMS/e-mail to complete a survey at baseline, and at 4 months and 12 months after receiving ECP or MS-2 Step (i.e. after entering the study).
- •**Consistent with current emergency contraception guidelines, there will be no age restriction (minimum or maximum age) on participants. Consumers seeking emergency contraception or MS-2 Step would be of reproductive age.
排除标准
- •Women requiring interpreting services
研究者
相似试验
招募中
3 期
A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone DeficiencyJPRN-jRCT2041210156Beckert Michael24
招募中
1 期
An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency.EUCTR2021-004313-39-ITAscendis Pharma Endocrinology Division A/S240
招募中
1 期
An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency.Adult Growth Hormone Deficiency (AGHD)MedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2021-004313-39-SKAscendis Pharma Endocrinology Division A/S240
进行中（未招募）
1 期
An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency.EUCTR2021-004313-39-GRAscendis Pharma Endocrinology Division A/S240
进行中（未招募）
不适用
A continuation study to assess long term safety of Lacosamide (approved drug in Europe) monotherapy and safety of Lacosamide monotherapy and Adjuctive therapy in people with partial-onset seizuresPartial-onset seizures (with and without secondary generalization)MedDRA version: 14.1Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2007-005440-25-Outside-EU/EEACB BIOSCIENCES, Inc.294